Setting new standards in information exchange for the pharmaceutical and biotech industry
Hear Agios CEO, Dr David Schenkein’s Keynote from the 2015 CMO East Summit
April 12, 2016
At the 2015 Chief Medical Officer Summit in Boston, David Schenkein, MD, CEO, Agios provided a warm and personal keynote sharing his journey as a Physician CEO. In this recording of the session, gain an insight into Dr. David Schenkein’s journey from physician to CEO of a biopharmaceutical company leading the way in the field of cancer metabolism. More specifically:
- The journey
- The people and mentor ships
- Prioritizing resources
- Successes and failures
- Overcoming hurdles
- Strategic partnerships
- Business planning
Listen to Dr Schenkein’s Session Here: http://www.blogtalkradio.com/pharmatalk/2015/09/21/the-journey-of-a-physician-ceo-with-david-schenkein-md-ceo-agios
About David Schenkein, MD, CEO, Agios
Dr Schenkein led the development of several first-in-class cancer therapeutics through all stages of development including the submission and approval of numerous NDAs, sBLAs and INDs. Dr. Schenkein served as Senior Vice President, Clinical Hematology/Oncology at Genentech with responsibility for leading the medical and scientific strategies for the Development BioOncology portfolio, as well as overseeing the BioOncology Clinical Science and Medical Science Liaison functions with a staff of more than 130 people. He is currently an adjunct Professor of Medicine at the Stanford University Cancer Center. Before his tenure at Genentech, he served as Senior Vice President of Clinical Research at Millennium Pharmaceuticals. While there, he led the clinical development of the drug candidate, Velcade® (bortezomib), which was approved during his tenure and has since become a blockbuster cancer therapy, significantly helping the lives of cancer patients. Prior to Millennium he was Director of the Cancer Center and Lymphoma Service at Tufts Medical Center.
The 2016 event is this May 11-12 in Boston. Learn more here.